Bullboard - Stock Discussion Forum Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology... see more

Add To Watchlist

TSX:CPH - Post Discussion

Cipher Pharmaceuticals Inc > Stifel Raises Target

View:

Post by retiredcf on Sep 25, 2024 9:17am

Stifel Raises Target

Stifel’s Justin Keywood moves his Cipher Pharmaceuticals Inc. target to $17 from $16 with a “buy” rating. The average is $17.63.

“We raise our target price ... to reflect increased confidence on integration efforts of Natroba but also as in the midst of a more prevalent lice season,” he said. “Cipher is a specialty pharma company, focused on dermatology with a high 60-per-cent EBITDA margin base business and strong FCF conversion. • The company announced the US$89.5-million acquisition of Natroba in July, which more than doubles the business’ EBITDA with free cash flow inflection, including from the use of $200-million in tax loss credits. • Natroba also has the commercial infrastructure to support a revenue level in excess of US$100-million, in our view, suggestive of additional operating leverage. • Our new $17.00 target reflects a slightly higher multiple and expected seasonal strength in Q3/Q4. • We estimate Cipher is still pursuing a pipeline of 25 assets to leverage the U.S. commercial infrastructure in-place.”

154